The week in pharma: action, reaction and insight – week to February 17, 2023

19 February 2023

By Barbara Obstoj-Cardwell. Editor

Research news featured last week, first with US pharma giant Bristol Myers Squibb and 2seventy bio presenting Phase III results for their CAR-T cell therapy Abecma (ide-cel) in multiple sclerosis. Also, G1 Therapeutics announced it was terminating a trial of its Cosela (trilaciclib) in colorectal cancer. Additionally, Pfizer released new Phase III data on its Talzenna in combination with Xtandi that missed one of its objectives. On the deal-making front, US drug developer Cullinan Oncology entered into a collaboration with China-based Harbour BioMed for the development of a potential cancer treatment, HBM7008/CLN-418, and USA-based Arrowhead Pharma revealed that Johnson & Johnson subsidiary Janssen has pulled out of a 2018 collaboration on the development of non-alcoholic steatohepatitis (NASH) candidate ARO-PNPLA3, formerly JNJ-75220795.

Positives and uncertainties in KarMMA-3 trial on ide-cel in earlier MM

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK